Richard Spaide, MD
Ophthalmology · New York, NYNPI 1730281957
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $1,093,031 of the $1,708,055 with a category attached, or 64.0%. Topcon Healthcare, Inc. accounts for 78.0% of it on its own, with 27 other manufacturers making up the rest. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $8804.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Topcon Healthcare, Inc.$1.3M
- Heidelberg Engineering, Inc.$201K
- F. Hoffmann-la Roche AG$75K
- Regeneron$25K
- Genentech, Inc.$23K
- Topcon Corporation$21K
- plus $32K from 22 others
Across 3 payments — averaging $8292.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Canon Inc.$24K
- F. Hoffmann-la Roche AG$688
What the payments were for
- Royalty or licence$1,093,03164%
- Consulting fees$566,82733%
- Speaking & faculty fees$9,0001%
- Travel & lodging$31,3582%
- Food & beverage$7,6510%
- Gifts$1880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Topcon Healthcare, Inc. | 57 | $1,331,450 |
| Heidelberg Engineering, Inc. | 8 | $201,048 |
| F. Hoffmann-la Roche AG | 9 | $74,884 |
| Regeneron | 8 | $25,228 |
| Genentech, Inc. | 14 | $22,748 |
| Topcon Corporation | 12 | $21,038 |
| Dutch Ophthalmic Research Center (international) B.v. | 2 | $7,093 |
| Janssen Global Services, LLC | 10 | $6,568 |
| Merck | 12 | $6,269 |
| Alcon Research LLC | 3 | $3,800 |
| Boehringer Ingelheim | 1 | $1,900 |
| Alcon | 3 | $1,519 |
| Eyepoint US, Inc. | 2 | $1,410 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $832 |
| Bausch & Lomb Americas Inc. | 6 | $467 |
| Genentech USA, Inc. | 17 | $427 |
| Carl Zeiss Meditec, Inc. | 1 | $310 |
| Topcon Healthcare Solutions, Inc. | 1 | $276 |
| Canon Inc. | 1 | $234 |
| Dutch Ophthalmic, USA | 1 | $109 |
| Regeneron Healthcare Solutions, Inc. | 3 | $102 |
| Apellis Pharmaceuticals, Inc. | 3 | $90 |
| Tarsus Pharmaceuticals, Inc. | 3 | $74 |
| Novartis | 4 | $73 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Amgen | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Alimera Sciences, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RETINAL CAMERAS$363,177
- SPAIDE FILTER$328,177
- Spectralis$201,048
- TRC-50DX$175,704
- SPAIDE (FAF) FILTERS$175,704
- NW500$150,007
- TRC-NW400$131,258
- OCT TRITON$85,788
- TRC NW-400$62,157
- TRC-NW-403$34,510
- OCT MAESTRO$33,288
- TRC-NW-402$29,625
- EYLEA$25,228
- TRC-NW-401$24,384
- DRI-OCT-TRITON$17,500
- VABYSMO$15,899
- Lucentis$7,339
- VisionBlue$4,278
- EVA Ophthalmic Surgical System$2,815
- EYP-1901$1,388
How this compares
$1,708,055 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alphagan PBrimonidine Tartrate | 11 | $3,220 |
| Bromfenac Sodium | 14 | $2,533 |
| Prednisolone Acetate | 32 | $1,194 |
| Travoprost | 15 | $1,156 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $1,030 |
| Brimonidine Tartrate | 15 | $762 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $493 |
| Timolol Maleate | 19 | $486 |
| Ketorolac Tromethamine | 11 | $427 |
| Latanoprost | 52 | $357 |
| Tobramycin | 13 | $80 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- David ChuNew York$234K
- Joshua KimNew York$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.